Cytovance garners $22.5M; Seattle ISB co-founder defects to research institute;

@FierceBiotech: Will Pfizer divest a big chunk of its operations? News | Follow @FierceBiotech

@JohnCFierce: Pfizer's David Schulz acknowledges R&D budget cuts but says the company is in the hunt and has money to spend. | Follow @JohnCFierce

> Cytovance Biologics today announced a growth equity investment of $22.5 million from Great Point Partners, LLC, a Greenwich, Connecticut private investment firm. Headquartered in Oklahoma City, OK, Cytovance is a contract manufacturer of mammalian and microbial biologics for biotechnology and pharmaceutical companies. Release

> The FDA has approved Gadavist (gadobutrol), a gadolinium-based contrast agent, for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system. Release

> The co-founder of Seattle's Institute for Systems Biology, Alan Aderem, is taking his team over to the Seattle Biomedical Research Institute, where he will become president. Story

> Cambridge, UK-based Xention is a partner in a new multidisciplinary atrial fibrillation research consortium, the 'European Network for Translational Research in Atrial Fibrillation,' which has been awarded a €12 million grant to engage in atrial fibrillation research. Xention release

> U.S. venture capitalist William K. Bowes, Jr. has donated $2 million to the Karolinska Institutet for an accelerator fund for talented young students. Release

Pharma News

> Portrait of an Indian Pharma acquisition 'failure'. Report

> FDA: Overseas manufacturing puts U.S. at risk. Article

> New law may mean harsher exec sentencing. Report

Biotech Research News

> Florida lawmakers tell Scripps to show them the jobs. Report

> Nanomaterials incarcerate prostate cancer cells. News 

> Genes are still looking hot, survey says. Item

> Research sheds light on anxiety disorders. Article 

> Pentagon may have hard time cutting cancer research budget. Story 

> Media report high hopes for adult stem cells. News 

Manufacturing News

> Cheers become jeers on KV's Makena pricing. News

> Pharma makes top-counterfeits list. Item

> Earthquake in Japan compromises supply chain. Report

> McNeil's consent decree terms could have been worse. Item 

> Decree a no-confidence vote in McNeil. Story

> USP edits drug labels for better patient compliance. Article

And Finally... The Alzheimer's Association says that there are almost 15 million unpaid caregivers for people living with Alzheimer's in the U.S. Report

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.